IP Library › Granted Patent US 10,888,631
Granted Patent B2
US 10,888,631 · App. 15/314,353 · Granted Jan 12, 2021

Lipid sterilization method

Inventors: Svein Kvale (Oslo, NO); Ingrid Henriksen (Oslo, NO); Ole Johannes Tokerud (Oslo, NO); Per Sontum (Oslo, NO)
Assignee: GE HEALTHCARE AS
A61L2/07A61K9/1075A61K9/1277A61K47/24A61K49/22A61K49/223A61B8/481
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,888,631
App. No.
15/314,353
Granted
Jan 12, 2021
Kind
B2
Abstract

The present invention relates to a method for sterilisation of phospholipid suspensions, useful in the preparation of ultrasound contrast agent precursors comprising phospholipid-stabilised perfluorobutane microbubbles. The method provides sterility assurance, without undue thermal degradation of the phospholipid. The method is also amenable to commercial scale manufacture. Also provided are methods of preparing kits and ultrasound contrast agents incorporating the sterilisation method of the invention.

Claims (13)

1. A method of sterilization of a suspension, which comprises:

(i) mixing a hydrogenated egg phosphatidylserine together with propylene glycol in an aqueous biocompatible carrier using a mixer of a jacketed vessel to give an aqueous hydrogenated egg phosphatidylserine suspension, wherein the suspension contacts an inner wall of the jacketed vessel and the mixer is provided within the jacketed vessel and is configured to mix the contents of the jacketed vessel;

(ii) autoclaving the aqueous hydrogenated egg phosphatidylserine suspension from step (i), wherein said autoclaving enables reaching F 0 values >15 in all parts of the sterilization system, and wherein heating, in addition to sensible heat from heating the jacket of said vessel, comprises the addition of steam to the headspace of the vessel of step (i) to obtain a hot suspension; and

(iii) cooling the hot suspension to 15 to 30° C. to give the sterile hydrogenated egg phosphatidylserine suspension, wherein the mass ratio of phospholipid to propylene glycol is 1:1.5 to 1:2.5.

2. The method of claim 1 , wherein the addition of steam to the headspace is performed multiple times during the autoclave cycle.

3. The method of claim 1 , further comprising the application of vacuum to the headspace of the vessel of step (i), before the addition of steam to said headspace.

4. The method of claim 1 , wherein the F 0 values reacted are between 15 and 25.

5. The method of claim 1 , wherein the content of phosphatidylserine (PS), relative to the sum of PS and related substances, in the sterile hydrogenated egg phosphatidylserine suspension of step (iii) is at least 68%.

6. The method of claim 5 , wherein the concentration of phosphatidic acid (PA), relative to the sum of PS and related substances, in the sterile p hydrogenated egg phosphatidylserine suspension of step (iii), is less than 15%.

7. The method of claim 6 , wherein the combined concentration of phosphatidylserine (PS) and phosphatidic acid (PA) in the sterile hydrogenated egg phosphatidylserine suspension of step (iii) is 5 mg/mL.

8. The method of claim 7 , wherein the mass ratio of the hydrogenated egg phosphatidylserine to propylene glycol is 1:2.

9. The method of claim 1 , wherein clean steam is used in step (ii).

10. The method of claim 1 , wherein a volume of the aqueous hydrogenated egg phosphatidylserine suspension of step (i) is in the range 20 to 80 L.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2016
From: HENRIKSEN, INGRID; KVALE, SVEIN; TOKERUD, OLE JOHANNES; SONTUM, PER
To: GE HEALTHCARE AS
Reel/Frame 040433/0238 →
Priority Claims (1)
GB 1411423.5 · Jun 26, 2014 · national
Continuity (1)
Related Publication 20170258950A1 · Sep 14, 2017